Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Stock Short Interest Declines 67.9%

Posted by Patrick Bannon on Oct 30th, 2026

Neuphoria Therapeutics Inc. (NASDAQ:NEUP – Get Free Report) was the recipient of a large decrease in short interest in the month of October. As of October 15th, there was short interest totaling 6,429 shares, a decrease of 67.9% from the September 30th total of 20,022 shares. Based on an average trading volume of 16,447 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.1% of the company’s shares are sold short.

Institutional Investors Weigh In On Neuphoria Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. ADAR1 Capital Management LLC bought a new stake in Neuphoria Therapeutics during the 2nd quarter worth approximately $131,000. Merck & Co. Inc. bought a new position in Neuphoria Therapeutics in the 2nd quarter valued at $43,818. Finally, AdvisorShares Investments LLC boosted its holdings in Neuphoria Therapeutics by 15.8% in the 1st quarter. AdvisorShares Investments LLC now owns 155,367 shares of the company’s stock valued at $632,000 after purchasing an additional 21,173 shares during the period. 15.90% of the stock is owned by hedge funds and other institutional investors.

Neuphoria Therapeutics Stock Performance

Shares of Neuphoria Therapeutics stock traded up $0.01 on Friday, hitting $3.06. The company had a trading volume of 68,813 shares, compared to its average volume of 87,599. Neuphoria Therapeutics has a 1 year low of $3.03 and a 1 year high of $5.53. The stock has a 50 day moving average of $3.59 and a 200-day moving average of $4.16. The stock has a market capitalization of $16.58 million, a price-to-earnings ratio of -0.49 and a beta of 0.75.

Analyst Ratings Changes

Several research firms have issued reports on NEUP. Weiss Ratings restated a “sell (d-)” rating on shares of Neuphoria Therapeutics in a report on Thursday, August 27th. Wall Street Zen upgraded shares of Neuphoria Therapeutics to a “hold” rating in a research report on Saturday, July 25th. Two equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Reduce” and a consensus target price of $7.00.

Read Our Latest Report on NEUP